POXEL

Poxel is a dynamic biopharmaceutical company developing innovative drugs for metabolic diseases, with a focus on type 2 diabetes and non-alcoholic steatohepatitis (NASH). Based in Lyon, France, Poxel was spun out in 2009 from Merck Serono, a global leader in the field of metabolic disorders at that time. They believe that targeting cellular energy regulation pathways for the treatment of metabolic diseases, including type 2 diabetes is of critical importance as disbalances are at the root of th... ose diseases. All three of their clinical stage pipeline programs address significant targets in the energy metabolism pathways. Imeglimin, their lead program, targets mitochondrial dysfunction, mitochondria being the power station of the cell, PXL770 activates the adenosine monophosphate-activated protein kinase (AMPK), an important energy sensor, and PXL065 (DRX-065) inhibits the mitochondrial pyruvate carrier (MPC).

#SimilarOrganizations #People #Financial #Event #Website #More

POXEL

Social Links:

Industry:

Biotechnology Health Diagnostics Pharmaceutical

Founded:

2009-01-01

Address:

Lyon, Rhone-Alpes, France

Country:

France

Website Url:

http://www.poxelpharma.com

Total Employee:

11+

Status:

Active

Contact:

+33144719855

Email Addresses:

[email protected]

Total Funding:

109.1 M USD

Technology used in webpage:

SPF Amazon Google Maps Google Maps API Amazon Virginia Region OVH DNS

Similar Organizations

reata-pharmaceuticals-logo

Reata Pharmaceuticals

Reata Pharmaceuticals is a biopharmaceutical company that develops drugs for cancer, inflammation, and neurodegenerative diseases.

Current Advisors List

pierre-legault_image

Pierre Legault Chairman of the Board of Directors @ Poxel
Board_member
2016-04-01

Current Employees Featured

david-e-moller_image

David E. Moller
David E. Moller Chief Scientific Officer @ Poxel
Chief Scientific Officer
2020-01-01

sophie-bozec_image

Sophie Bozec
Sophie Bozec Senior Vice President, R&D Pharmacology, Co-Founder @ Poxel
Senior Vice President, R&D Pharmacology, Co-Founder

pascale-fouqueray_image

Pascale Fouqueray
Pascale Fouqueray Executive Vice President, Early Development and Translational Medicine, Co-Founder @ Poxel
Executive Vice President, Early Development and Translational Medicine, Co-Founder
2009-01-01

not_available_image

Elizabeth Woo
Elizabeth Woo SVP, Investor Relations, Public Relations & Corporate Communications @ Poxel
SVP, Investor Relations, Public Relations & Corporate Communications
2021-08-01

christophe-arbet-engels_image

Christophe Arbet-Engels
Christophe Arbet-Engels Chief Medical Officer, Executive Vice President, Late Development & Medical Affairs @ Poxel
Chief Medical Officer, Executive Vice President, Late Development & Medical Affairs
2017-01-01

thomas-kuhn_image

Thomas Kuhn
Thomas Kuhn Chief Executive Officer, Co-Founder @ Poxel
Chief Executive Officer, Co-Founder
2009-01-01

sébastien-bolze_image

Sébastien Bolze
Sébastien Bolze Executive Vice President, Non Clinical Development, Co-Founder @ Poxel
Executive Vice President, Non Clinical Development, Co-Founder

anne-renevot_image

Anne Renevot
Anne Renevot Chief Financial Officer @ Poxel
Chief Financial Officer
2017-05-01

Founder

pascale-fouqueray_image

Pascale Fouqueray

sophie-bozec_image

Sophie Bozec

sébastien-bolze_image

Sébastien Bolze

thomas-kuhn_image

Thomas Kuhn

Stock Details

Company's stock symbol is EPA:POXEL

Investors List

ipf-partners_image

Key Employee Changes

Date	New article
2021-09-02	Poxel Appoints Elizabeth Woo as Senior Vice President, Investor Relations, Public Relations and Corporate Communications, Based in Boston
2020-01-23	Poxel Appoints Industry Leader Dr. David E. Moller as Chief Scientific Officer

Official Site Inspections

http://www.poxelpharma.com Semrush global rank: 3.87 M Semrush visits lastest month: 3.33 K

Host Informations
Whois Informations

Loading ...